{"id":531047,"date":"2021-02-20T18:34:02","date_gmt":"2021-02-20T18:34:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=531047"},"modified":"2021-02-20T18:34:02","modified_gmt":"2021-02-20T18:34:02","slug":"cholangiocarcinoma-market-insights-epidemiology-and-market-forecast-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cholangiocarcinoma-market-insights-epidemiology-and-market-forecast-by-delveinsight_531047.html","title":{"rendered":"Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast by DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1613629940.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1613629940.png\" alt=\"Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast by DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\"><strong>DelveInsight has launched a new report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Cholangiocarcinoma Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Cholangiocarcinoma (CCA) is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from any portion of the bile duct i.e., from terminal ductules (canals of Hering) to the ampulla of Vater, as well as at the peribiliary glands (intramural and extramural) and sometimes may affect gall bladder.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample copy<\/strong>&#8211;<strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The <strong>Cholangiocarcinoma Market<\/strong> report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM <strong>Cholangiocarcinoma Market<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cholangiocarcinoma Treatment Market<\/strong><\/p>\n<p style=\"text-align: justify;\">Inflammation, cholestasis and receptor tyrosine kinases such as IL-6 receptor, c-MET and the EGFR family members are key signaling pathways in cholangiocarcinogenesis. It can be classified anatomically based on tumor location within the biliary tree into intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) cholangiocarcinoma subtypes. The latter two subtypes were previously grouped as extrahepatic CCA (eCCA) but are now considered distinct entities based upon differences in their tumor biology and management.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cholangiocarcinoma Market Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Agios Pharmaceuticals<\/li>\n<li>AstraZeneca<\/li>\n<li>QED Therapeutics<\/li>\n<li>Merck\/EMD Serono<\/li>\n<li>Nucana<\/li>\n<li>And many others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cholangiocarcinoma Market Report<\/strong><\/p>\n<p style=\"text-align: justify;\">CCA is coded as intrahepatic bile duct carcinoma (C22.1), extrahepatic bile duct carcinoma (C24.0), Ampulla of Vater (C24.1), overlapping lesion of biliary tract (C24.8) (includes malignant neoplasm of biliary tract whose point of origin cannot be classified to any one of the categories); or it involves both intrahepatic and extrahepatic bile ducts (C22.0-C24.1), and Biliary tract unspecified (C24.9).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cholangiocarcinoma Market Report Scope<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Cholangiocarcinoma (CCA), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Cholangiocarcinoma (CCA) epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Cholangiocarcinoma (CCA) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Cholangiocarcinoma (CCA) market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cholangiocarcinoma (CCA) market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample copy<\/strong>&#8211; <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of content<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Key Insights<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>2. Executive Summary of Cholangiocarcinoma (CCA)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>3. Competitive Intelligence Analysis for Cholangiocarcinoma (CCA)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>4. Cholangiocarcinoma (CCA): Market Overview at a Glance<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>5. Cholangiocarcinoma (CCA): Disease Background and Overview<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>6. Patient Journey<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>7. Cholangiocarcinoma (CCA) Epidemiology and Patient Population<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8. Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9. Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>10. Key Endpoints of Cholangiocarcinoma (CCA) Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11. Marketed Products<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12. Emerging Therapies<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>13. Cholangiocarcinoma (CCA): Seven Major Market Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>14. Attribute analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>15. 7MM: Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>16. Access and Reimbursement Overview of Cholangiocarcinoma (CCA)<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>17. KOL Views<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>18. Market Drivers<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>19. Market Barriers<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>20. Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>21. DelveInsight Capabilities<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>22. Disclaimer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>23. About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>What are the reasons to buy?<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report will help in developing business strategies by understanding trends shaping and driving the Cholangiocarcinoma (CCA) market<\/li>\n<li>To understand the future market competition in the Cholangiocarcinoma (CCA) market and Insightful review of the key market drivers and barriers<\/li>\n<li>Organize sales and marketing efforts by identifying the best opportunities for Cholangiocarcinoma (CCA) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan<\/li>\n<li>Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors<\/li>\n<li>Organize sales and marketing efforts by identifying the best opportunities for Cholangiocarcinoma (CCA) market<\/li>\n<li>To understand the future market competition in the Cholangiocarcinoma (CCA) market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholangiocarcinoma-cca-epidemiology-forecast\" target=\"_blank\">Cholangiocarcinoma Epidemiology<\/a><\/strong><\/li>\n<li><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholangiocarcinoma-cca-pipeline-insight\" target=\"_blank\">Cholangiocarcinoma&nbsp;Pipeline<\/a><\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cholangiocarcinoma-market-insights-epidemiology-and-market-forecast-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cholangiocarcinoma-market-insights-epidemiology-and-market-forecast-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight has launched a new report on Cholangiocarcinoma Market &nbsp; Cholangiocarcinoma (CCA) is a rare and heterogeneous malignant neoplasm with epithelial cell origin of biliary duct and histologic and biochemical features of cholangiocyte differentiation. The malignant tumor may arise from &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cholangiocarcinoma-market-insights-epidemiology-and-market-forecast-by-delveinsight_531047.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,417,419,406,413],"tags":[],"class_list":["post-531047","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Marketing-Sales","category-Media-Communications","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=531047"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/531047\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=531047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=531047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=531047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}